|
With the wide application of high-throughput sequencing and the development of multiomics analysis, somatic mutational profiling has demonstrated that there is heterogeneity across multiple malignancies. Meanwhile, tumor mutational burden (TMB) was proven to be effective predictors of immunotherapy response. However, the significance of TMB in predicting prognosis remains unclear.
|